Prof. Enrique Gallardo, Parc Taulí University Hospital, Spain
Prof. Gallardo analyzes the final overall survival results of enzalutamide combined with radium-223 in metastatic castration-resistant prostate cancer (mCRPC). He discusses how these data may influence clinical practice, identifies patient populations most likely to benefit, and examines key considerations for safety management. The conversation also explores future research directions for optimizing combination strategies in advanced prostate cancer.
Watch the full interview for detailed insights and expert perspectives.